CYDY News and Press, CytoDyn Inc From 07/08/20

VANCOUVER, Washington, July 08, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced...

CytoDyn ( CYDY ) is starting to attract some attention from all corners of the market, including some of the best champions of the bears. Notorious bear research firm, Citron Research, has been summoned to take on the seemingly unstoppable CYDY that has run-over previous challengers, including...

Change in Location of the Special Meeting to be held on July 22, 2020  Meeting Date: July 22, 2020 Meeting Time: 9:30 a.m. (Pacific Time) Meeting Access:   http://www.meetingcenter.io/285700571 VANCOUVER, Washington, July 08, 2020 (GLOBE NEWSWIRE) -- Due to the...

Results of preclinical study presented today in oral presentation at the 23 rd International AIDS Conference (AIDS 2020)  VANCOUVER, Washington, July 07, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biot...

Will an anti- COVID-19 vaccine be effective? Much has been written about the potential of multiple vaccines to ultimately prevent COVID-19, the condition caused by the SARS-CoV-2 coronavirus. However, despite Operation Warp Speed and the immense hyperbole surrounding vaccine candidates in...

This Agreement will allow for immediate distribution of leronlimab to patients for the treatment of COVID-19 upon successful completion of CytoDyn’s ongoing clinical trials and FDA approval VANCOUVER, Washington, July 06, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (...

CytoDyn ( OTCQB:CYDY ) has signed an exclusive Distribution and Supply Agreement with American Regent, a Daiichi Sankyo Group company for the  distribution of leronlimab for the treatment of COVID-19 in the U.S. More news on: CytoDyn Inc., Healthcare stocks news, Read more ...

This Agreement will allow for immediate distribution of leronlimab to patients for the treatment of COVID-19 upon successful completion of CytoDyn’s ongoing clinical trials and FDA approval VANCOUVER, Washington, July 03, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) ...

           Dr. Pourhassan and Mobeen Syed, M.D., M.S. will discuss the Company’s multi-pathway to exploring the many potential opportunities for leronlimab, including COVID-19 VANCOUVER, Washington, July 03, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OT...

Source If valuing a company was as easy as attaching an intrinsic value based on an investor ratio such as price-to-earnings or price-to-cash flow, or even a discounted cash flow method, it would have been really difficult to lose money in the stock market. Numbers, most certainly, play an...